- Home
- NUAI vs BRTX Comparison
NUAI vs BRTX Comparison
Compare NUAI & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUAI
- BRTX
- Stock Information
- Founded
- NUAI N/A
- BRTX 1997
- Country
- NUAI United States
- BRTX United States
- Employees
- NUAI N/A
- BRTX N/A
- Industry
- NUAI Oil & Gas Production
- BRTX Managed Health Care
- Sector
- NUAI Energy
- BRTX Health Care
- Exchange
- NUAI Nasdaq
- BRTX Nasdaq
- Market Cap
- NUAI 11.3M
- BRTX 12.5M
- IPO Year
- NUAI N/A
- BRTX N/A
- Fundamental
- Price
- NUAI $0.40
- BRTX $1.54
- Analyst Decision
- NUAI
- BRTX
- Analyst Count
- NUAI 0
- BRTX 0
- Target Price
- NUAI N/A
- BRTX N/A
- AVG Volume (30 Days)
- NUAI 7.1M
- BRTX 96.3K
- Earning Date
- NUAI 08-14-2025
- BRTX 11-11-2025
- Dividend Yield
- NUAI N/A
- BRTX N/A
- EPS Growth
- NUAI N/A
- BRTX N/A
- EPS
- NUAI N/A
- BRTX N/A
- Revenue
- NUAI $718,761.00
- BRTX $605,200.00
- Revenue This Year
- NUAI N/A
- BRTX $232.67
- Revenue Next Year
- NUAI N/A
- BRTX $52.92
- P/E Ratio
- NUAI N/A
- BRTX N/A
- Revenue Growth
- NUAI 14.80
- BRTX 247.62
- 52 Week Low
- NUAI $0.32
- BRTX $1.21
- 52 Week High
- NUAI $12.29
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- NUAI N/A
- BRTX 45.25
- Support Level
- NUAI N/A
- BRTX $1.56
- Resistance Level
- NUAI N/A
- BRTX $1.63
- Average True Range (ATR)
- NUAI 0.00
- BRTX 0.10
- MACD
- NUAI 0.00
- BRTX -0.01
- Stochastic Oscillator
- NUAI 0.00
- BRTX 8.97
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.